Open access
Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab ARROYO Study.
E. Rodríguez-Suárez
M. Cardner
D. Muthas
C. Chamberlain
Adam Platt
S. Altrichter
Lisa A. Beck
J. Bernstein
A. Giménez-Arnau
M. Metz
Christopher McCrae
Medicine
Abstract
In this post hoc analysis funded by AstraZeneca, benralizumab reduced eosinophil‐related protein biomarker expression. Benralizumab reduced eosinophil‐derived neurotoxin concentrations, which were dose‐independent and irrespective of BHRA status.